Yahoo
Stockholm - Delayed Quote SEK

BioGaia AB (publ) (BIOG-B.ST)

120.40 +0.50 (+0.42%)
At close: October 30 at 12:59:49 PM GMT+1
Chart Range Bar
Loading chart for BIOG-B.ST
  • Previous Close 119.90
  • Open 119.60
  • Bid 120.10 x --
  • Ask 120.40 x --
  • Day's Range 119.30 - 120.70
  • 52 Week Range 96.20 - 136.30
  • Volume 84,745
  • Avg. Volume 183,370
  • Market Cap (intraday) 12.18B
  • Beta (5Y Monthly) 0.27
  • PE Ratio (TTM) 31.11
  • EPS (TTM) 3.87
  • Earnings Date Oct 22, 2026
  • Forward Dividend & Yield 1.64 (1.36%)
  • Ex-Dividend Date May 8, 2026
  • 1y Target Est 158.00

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment offers packaging solutions. It sells its products through distribution partners or through its own distribution channels. The company was incorporated in 1990 and is headquartered in Stockholm, Sweden.

www.biogaiagroup.com

251

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

BIOG-B.ST
16.95%
OMX Stockholm 30 Index (^OMX)
13.47%

1-Year Return

BIOG-B.ST
22.73%
OMX Stockholm 30 Index (^OMX)
17.56%

3-Year Return

BIOG-B.ST
41.87%
OMX Stockholm 30 Index (^OMX)
59.03%

5-Year Return

BIOG-B.ST
40.45%
OMX Stockholm 30 Index (^OMX)
42.80%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 400.4M
Earnings 110.21M
Profit Margin 27.52%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
100M
200M
300M
400M
22.0%
24.0%
26.0%

Analyst Insights

View More

Analyst Price Targets

151.00
158.00 Average
120.40 Current
165.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    23.67%

  • Return on Assets (ttm)

    19.86%

  • Return on Equity (ttm)

    32.10%

  • Revenue (ttm)

    1.65B

  • Net Income Avi to Common (ttm)

    391.56M

  • Diluted EPS (ttm)

    3.87

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    518.28M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    168.37M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: